HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adaptimmune Therapeutics plc

https://www.adaptimmune.com/

Latest From Adaptimmune Therapeutics plc

Cutting-Edge Biologics Approvals, Trials Pick Up In Korea After New Law

Novartis among the first to benefit with approvals for Zolgensma, Kymriah, and Luxturna. The new law has also enabled its first clinical trial – a Phase Ib study by Seoul National University of a CAR-T therapy for recurrent or refractory, CD19-positive, B-cell acute lymphoblastic leukemia.

South Korea Biologics

Value Of BioPharma M&A Leaps in Q3

Merck & Co's proposed acquisition of Acceleron and a couple of big purchases from Sanofi drove up the value of the sector's M&A activities, according to the latest report from Biomedtracker

M & A Deals

Bluebird Spinoff 2seventy Bio Gets Its Own Wings

The formal split between the companies had been in the works since January, with 2seventy set to take over oncology operations while bluebird focuses on gene therapies.

Business Strategies Biologics

Adaptimmune/Genentech Deal Gives Powerful Push To Solid Tumor Cell Therapies

Adaptimmune is getting a leg up in the race to develop iPSC-derived allogeneic cell therapies in a deal with the Roche subsidiary worth potentially more than $3bn.

Deals Gene Therapy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Adaptimmune LLC
    • Adaptimmune Ltd.
UsernamePublicRestriction

Register